KR102172228B1 - 재조합 프로바이오틱 세균 - Google Patents

재조합 프로바이오틱 세균 Download PDF

Info

Publication number
KR102172228B1
KR102172228B1 KR1020177024852A KR20177024852A KR102172228B1 KR 102172228 B1 KR102172228 B1 KR 102172228B1 KR 1020177024852 A KR1020177024852 A KR 1020177024852A KR 20177024852 A KR20177024852 A KR 20177024852A KR 102172228 B1 KR102172228 B1 KR 102172228B1
Authority
KR
South Korea
Prior art keywords
factor
lactobacillus
growth factor
acid sequence
recombinant probiotic
Prior art date
Application number
KR1020177024852A
Other languages
English (en)
Korean (ko)
Other versions
KR20170118772A (ko
Inventor
토마스 워스
유하 이르잔헤이키
하리타 사마라나야케
딕 웨버
이고르 미에라우
피터 알라드 브론
헤르비그 바흐만
Original Assignee
아우리얼리스 오와이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아우리얼리스 오와이 filed Critical 아우리얼리스 오와이
Publication of KR20170118772A publication Critical patent/KR20170118772A/ko
Application granted granted Critical
Publication of KR102172228B1 publication Critical patent/KR102172228B1/ko

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2026IL-4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]
    • C07K14/503Fibroblast growth factor [FGF] basic FGF [bFGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/53Colony-stimulating factor [CSF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5406IL-4
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11Medicinal preparations comprising living procariotic cells
    • A61K2035/115Probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)
KR1020177024852A 2015-02-04 2015-11-02 재조합 프로바이오틱 세균 KR102172228B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2015/052345 WO2016124239A1 (en) 2015-02-04 2015-02-04 Recombinant probiotic bacteria for use in the treatment of a skin dysfunction
EPPCT/EP2015/052345 2015-02-04
PCT/EP2015/075484 WO2016124266A1 (en) 2015-02-04 2015-11-02 Recombinant probiotic bacteria

Publications (2)

Publication Number Publication Date
KR20170118772A KR20170118772A (ko) 2017-10-25
KR102172228B1 true KR102172228B1 (ko) 2020-11-02

Family

ID=53039847

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177024852A KR102172228B1 (ko) 2015-02-04 2015-11-02 재조합 프로바이오틱 세균

Country Status (27)

Country Link
US (1) US10738315B2 (ru)
EP (1) EP3253402B1 (ru)
JP (1) JP6726419B2 (ru)
KR (1) KR102172228B1 (ru)
CN (1) CN107438666B (ru)
AU (1) AU2015381262B2 (ru)
BR (1) BR112017016772A2 (ru)
CA (1) CA2975636C (ru)
CY (2) CY20182200002T2 (ru)
DE (1) DE15821025T8 (ru)
DK (1) DK3253402T3 (ru)
ES (1) ES2673007T3 (ru)
HR (1) HRP20200973T1 (ru)
HU (1) HUE050790T2 (ru)
IL (1) IL253782B (ru)
LT (1) LT3253402T (ru)
MX (1) MX2017010150A (ru)
NZ (1) NZ734579A (ru)
PL (1) PL3253402T3 (ru)
PT (1) PT3253402T (ru)
RS (1) RS60437B1 (ru)
RU (1) RU2723324C2 (ru)
SG (1) SG11201706398VA (ru)
SI (1) SI3253402T1 (ru)
TR (1) TR201808169T3 (ru)
WO (2) WO2016124239A1 (ru)
ZA (1) ZA201705812B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6581208B2 (ja) 2014-12-23 2019-09-25 イリヤ ファーマ エービー 創傷治癒の方法
CN109983028B (zh) 2016-09-13 2023-10-20 英特瑞克斯顿阿克图比奥帝克斯有限公司 黏膜黏附性微生物
US11850270B2 (en) 2017-12-04 2023-12-26 The BioCollective, LLC Probiotics and methods of use
AU2019223439A1 (en) * 2018-02-24 2020-09-10 Clearskin Ltd Compositions, devices, systems, kits and methods for the treatment of a skin condition
US20230240348A1 (en) * 2018-06-19 2023-08-03 Coenbio Co., Ltd. Composition for improving liver function comprising leuconostoc sp. strain
EP3837993A4 (en) * 2018-06-19 2022-04-20 Coenbio Co., Ltd. COMPOSITION FOR IMPROVING INTESTINAL FUNCTION WITH LEUCONOSTOC SP. STRAIN
KR102283127B1 (ko) * 2018-06-19 2021-07-29 주식회사 엠디헬스케어 류코노스톡속 균주를 포함하는 간 기능 개선용 조성물
KR102173168B1 (ko) * 2018-06-19 2020-11-03 주식회사 엠디헬스케어 류코노스톡속 균주를 포함하는 장 기능 개선용 조성물
WO2020031204A1 (en) * 2018-08-08 2020-02-13 Sree Chitra Tirunal Institute For Medical Science And Technology Recombinant tgf α for wound healing purposes, and the process thereof
CN109078171A (zh) * 2018-09-10 2018-12-25 因之彩生物科技(武汉)有限公司 一种外用组合物及其应用以及外用治疗剂
IT201900003115A1 (it) * 2019-03-04 2020-09-04 Univ Degli Studi Roma La Sapienza Lattococco ingegnerizzato
HRP20240085T1 (hr) * 2019-03-04 2024-03-29 Aurealis Therapeutics AG Prokariotski ekspresijski sustav indukciran kloridom
CN112175890A (zh) * 2019-07-02 2021-01-05 深伦生物科技(深圳)有限公司 一种以食用菌分泌乙醇脱氢酶的基因工程菌
KR102343938B1 (ko) * 2020-09-02 2021-12-28 주식회사 비피도 재조합 비피도박테리움 비피덤 bgn4를 포함하는 염증 개선용 조성물
CN112359049B (zh) * 2020-12-10 2022-01-28 昆明理工大学 一种岷江百合几丁质酶基因LrCHI2及其应用
KR102253283B1 (ko) * 2020-12-21 2021-05-18 주식회사 비피도 비피도박테리움 비피덤을 이용한 인간 egf 단백질의 생산방법 및 이를 함유하는 조성물
JP2024508541A (ja) * 2021-03-05 2024-02-27 ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニア 皮膚プロバイオティクス
CN114395514B (zh) * 2022-02-28 2023-09-01 鲁东大学 一株嗜酸乳杆菌、菌剂及其应用
CN114957437B (zh) * 2022-06-06 2023-03-21 陕西理工大学 一种leap-2重组蛋白和一种重组乳酸乳球菌及其应用
CN115181710B (zh) * 2022-09-13 2022-11-25 北京量化健康科技有限公司 一株唾液乳杆菌b12wu及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008155120A2 (en) 2007-06-20 2008-12-24 Actogenix Nv Methods and compositions for treating mucositis
WO2009114702A2 (en) 2008-03-14 2009-09-17 Humanzyme Limited Recombinant production of authentic human proteins using human cell expression systems
WO2011150127A2 (en) 2010-05-25 2011-12-01 The Board Of Trustees Of The University Of Illinois Novel systems, vectors, and methods for delivery of biomolecules to eukaryotic cells
WO2011159880A1 (en) 2010-06-18 2011-12-22 North Carolina State University Recombinant lactobacillus with decreased lipoteichoic acid to reduce inflammatory responses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1751270A1 (en) 2004-05-18 2007-02-14 VIB vzw Self-containing lactobacillus strain
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
KR101557509B1 (ko) 2007-01-12 2015-10-06 액토제닉스 엔.브이. 락토코커스 프로모터 및 그것의 용도
JP2012504390A (ja) * 2008-09-30 2012-02-23 ノボザイムス,インコーポレイティド 糸状菌細胞におけるポジティブ及びネガティブ選択遺伝子の使用方法
AU2009314165B2 (en) 2008-11-11 2014-05-15 Signum Biosciences, Inc. Isoprenyl compounds and methods thereof
JP2012515721A (ja) * 2009-01-20 2012-07-12 シグナム バイオサイエンシーズ, インコーポレイテッド 抗炎症性複合体
FR2948868B1 (fr) * 2009-08-07 2011-10-07 Anthogyr Sa Piece a main a moyens de connexion electrique
BR112012016982B8 (pt) * 2010-01-14 2022-12-20 Institut National De Rech Pour Lagriculture Lalimentation Et Lenvironnement bactéria de ácido lático recombinante de grau alimentício e composição terapêutica
CN101892189B (zh) 2010-07-05 2012-07-04 浙江大学 一种口服免疫阻断猪生长抑素作用的转化子及其应用
JP2012019768A (ja) * 2010-07-16 2012-02-02 Osaka Univ Jmjd3遺伝子改変非ヒト哺乳動物、Jmjd3遺伝子改変骨髄キメラ非ヒト哺乳動物、及びその利用
TWI566701B (zh) 2012-02-01 2017-01-21 日本農藥股份有限公司 芳烷氧基嘧啶衍生物及包含該衍生物作為有效成分的農園藝用殺蟲劑及其使用方法
GB201206599D0 (en) 2012-04-13 2012-05-30 Univ Manchester Probiotic bacteria
TWI613833B (zh) 2012-11-09 2018-02-01 Sony Corp 光電變換元件、固體攝像裝置及電子機器
CN104797251A (zh) * 2012-11-16 2015-07-22 阿勒根公司 用前列腺素ep4激动剂组合进行皮肤创伤治愈和疤痕减少
CN106661543A (zh) * 2014-06-17 2017-05-10 Xycrobe治疗公司 经遗传修饰的细菌和用于细菌的遗传修饰的方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008155120A2 (en) 2007-06-20 2008-12-24 Actogenix Nv Methods and compositions for treating mucositis
WO2009114702A2 (en) 2008-03-14 2009-09-17 Humanzyme Limited Recombinant production of authentic human proteins using human cell expression systems
WO2011150127A2 (en) 2010-05-25 2011-12-01 The Board Of Trustees Of The University Of Illinois Novel systems, vectors, and methods for delivery of biomolecules to eukaryotic cells
WO2011159880A1 (en) 2010-06-18 2011-12-22 North Carolina State University Recombinant lactobacillus with decreased lipoteichoic acid to reduce inflammatory responses

Also Published As

Publication number Publication date
PT3253402T (pt) 2020-07-07
RU2017127991A3 (ru) 2019-03-04
CY1123065T1 (el) 2021-10-29
RU2017127991A (ru) 2019-03-04
NZ734579A (en) 2019-10-25
CN107438666B (zh) 2021-08-17
US20180135062A1 (en) 2018-05-17
BR112017016772A2 (pt) 2018-04-17
HRP20200973T1 (hr) 2020-10-02
ES2673007T1 (es) 2018-06-19
AU2015381262A1 (en) 2017-08-17
HUE050790T2 (hu) 2021-01-28
LT3253402T (lt) 2020-06-10
CY20182200002T2 (el) 2018-09-05
ZA201705812B (en) 2019-12-18
EP3253402A1 (en) 2017-12-13
EP3253402B1 (en) 2020-04-29
HUE15821025T1 (hu) 2018-12-28
MX2017010150A (es) 2018-06-15
WO2016124239A1 (en) 2016-08-11
DK3253402T1 (da) 2018-06-18
PL3253402T3 (pl) 2021-02-08
ES2673007T3 (es) 2021-01-22
RS60437B1 (sr) 2020-07-31
DE15821025T8 (de) 2018-09-13
CA2975636C (en) 2022-12-06
TR201808169T3 (tr) 2018-07-23
SG11201706398VA (en) 2017-09-28
WO2016124266A1 (en) 2016-08-11
AU2015381262B2 (en) 2019-03-28
IL253782B (en) 2022-04-01
DE15821025T1 (de) 2018-07-26
JP2018509932A (ja) 2018-04-12
RU2723324C2 (ru) 2020-06-09
KR20170118772A (ko) 2017-10-25
SI3253402T1 (sl) 2020-08-31
JP6726419B2 (ja) 2020-07-22
US10738315B2 (en) 2020-08-11
DK3253402T3 (da) 2020-06-02
CN107438666A (zh) 2017-12-05
IL253782A0 (en) 2017-09-28
CA2975636A1 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
KR102172228B1 (ko) 재조합 프로바이오틱 세균
EP3237622B1 (en) Methods for wound healing
KR101411839B1 (ko) Abc 트랜스포터를 통한 egf 분비 재조합 미생물 및 이를 유효성분으로 포함하는 소화기 궤양 개선 또는 치료용 조성물
US9730968B2 (en) Therapeutic agent for ischemic diseases
KR102602358B1 (ko) 염화물-유도성 원핵생물 발현 시스템
EP3249043A1 (en) Therapeutic agent for ischemic diseases
EP2733207A1 (en) Ischemic disease therapeutic agent
US20130095072A1 (en) Therapeutic agent for ischemic diseases
RU2812766C2 (ru) Хлорид-индуцируемая прокариотическая система экспрессии
US20220152127A1 (en) Engineered lactococcus

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
X091 Application refused [patent]
AMND Amendment
X701 Decision to grant (after re-examination)
GRNT Written decision to grant